Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus

Abstract

Lichen planus (LP) is a chronic inflammatory disease affecting the skin and mucosa of squamous cell origin and has a significantly higher prevalence in patients infected with the hepatitis C virus (HCV). Although ribavirin-based treatments frequently show exacerbations of these lesions, currently there is little information on the response of HCV-associated LP to newer direct antiviral agents (DAA), such as ledipasvir-sofosbuvir (Harvoni; Gilead Sciences, Foster City, CA).